Currently, chronic diffuse liver disease (CDLD) takes an important place among the causes of early disability and mortality of the
population. The main etiological factors are: hepatotropic viruses, action of xenobiotics (alcohol and drugs), metabolic disorders.
The toxic and metabolic liver injuries have common stages of pathogenesis, including the activation of lipid peroxidation,
oxidative stress, phospholipid damage to mitochondrial membranes, and the disorders in the systemic and cellular links of
lipid metabolism. The search for effective therapy, preventive measures and the ability to effect the pathogenesis of CDLD are
important problems of modern hepatology. The use of the drug Methadoxil has shown good results in clinical practice, due to its
proven antioxidant and antifibrotic properties, and its ability to normalize the composition of the lipid layer of the hepatocyte
membrane. Metadoxine metabolites, such as coenzymes, participate in the hepatic metabolism of carbohydrates, bile acids and
amino acids, increase the rate of utilization of ethanol and acetaldehyde. Metadoxil has a direct cholinergic effect on the central
nervous system, which is accompanied by an antidepressant, psychostimulating action. When used in chemotherapy, the drug
does not reduce the effect of cytostatics, does not provoke toxic reactions associated with the use of cytotoxic agents. Metadoxil
is well tolerated and does not have significant side effects.